Group One Trading
MLTX icon

Group One Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Group One Trading’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$624K Buy
33,500
+3,000
+10% +$49.7K ﹤0.01% 3141
2025
Q4 		$402K Sell
30,500
-92,600
-75% -$1.09M ﹤0.01% 3735
2025
Q3 		$883K Buy
123,100
+34,800
+39% +$1.81M ﹤0.01% 3161
2025
Q2 		$4.17M Buy
88,300
+88,000
+29,333% +$3.58M 0.01% 1467
2025
Q1 		$11.7K Sell
300
-65,400
-100% -$2.82M ﹤0.01% 6154
2024
Q4 		$3.56M Buy
65,700
+100
+0.2% +$5.11K 0.01% 1420
2024
Q3 		$3.31M Sell
65,600
-800
-1% -$37.5K 0.01% 1335
2024
Q2 		$2.92M Sell
66,400
-3,500
-5% -$148K 0.01% 1159
2024
Q1 		$3.51M Buy
69,900
+47,700
+215% +$2.59M 0.01% 1074
2023
Q4 		$1.34M Buy
22,200
+3,500
+19% +$180K ﹤0.01% 2190
2023
Q3 		$1.07M Buy
+18,700
New +$1.03M ﹤0.01% 2200

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading's MLTX Position: Q1 2026 in Review

Group One Trading reduced its MoonLake Immunotherapeutics (MLTX) stake by 29% in Q1 2026, selling an estimated $148K and leaving 21,563 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #3544.

Group One Trading first reported a position in MLTX in Q3 2023 and has held it in 6 quarters since. The position peaked at $679K in Q1 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Group One Trading held 21,563 shares of MoonLake Immunotherapeutics worth $402K as of Q1 2026.
  • Group One Trading sold 8,913 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $148K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3544 holding.
  • Group One Trading first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 6 quarters since.
  • Group One Trading's MoonLake Immunotherapeutics position peaked at $679K in Q1 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.